Steve Cutler, CEO of a biotech company, discusses the uncertain state of biotech demand and recovery pace. While optimistic about long-term prospects, the next few quarters remain unpredictable due to delayed decision-making. Revenue growth is expected for 2025, with evolving business mix and potential margin implications.